Organization

Newcastle University

1 clinical trial

9 abstracts

Abstract
Node marking techniques and targeted axillary dissection in patients with cN1 disease undergoing neoadjuvant chemotherapy: Analysis of initial 500 participants in the ATNEC trial.
Org: Royal Derby Hospital, University of Warwick, Aberdeen Royal Infirmary, Royal Cornwall Hospitals NHS Trust, Queen Elizabeth Hospital,
Abstract
A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors.
Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Newcastle University, Northern Centre for Cancer Care (NCCC), New Experimental Therapeutics (NEXT), Merck Serono Ltd.,
Clinical trial
Phase 1 Study of Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis
Status: Completed, Estimated PCD: 2018-11-01
Abstract
Discovery and validation of AMBLor as a prognostic biomarker for non-ulcerated cutaneous AJCC stage I/II melanoma.
Org: Newcastle University, Hospital Clinico Universitario de Valencia; INCLIVA; GEICAM Spanish Breast Cancer Group, University of Barcelona, Hospital Clinic of Barcelona, Dermatology Department,
Abstract
“LIKE A BAG OF LIQUORICE ALLSORTS – EVERYBODY'S GOT DIFFERENT FLAVOURS”: A QUALITATIVE FOCUS GROUP STUDY TO EXPLORE SYMPTOMS OF FATIGUE, SLEEP DISTURBANCES AND PAIN IN PRIMARY SJÖGREN'S SYNDROME PATIENTS AND TO DEVELOP A FUTUR
Org: Newcastle University, Newcastle upon Tyne NHS Foundation Trust, Northumbria University, Newcastle upon Tyne, University of East Anglia, Norwich, United Kingdom,
Abstract
‘CLINICAL ASSESSMENT OF THE MUSCULOSKELETAL SYSTEM’ HANDBOOK AND ACCOMPANYING VIDEOS: 15 YEARS OF USE
Org: Newcastle University, Cardiff University School of Medicine, Versus Arthritis, City Hospitals Sunderland,
Abstract
ABATACEPT IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS: RESULTS FROM THE ARTHRITIS PREVENTION IN THE PRE-CLINICAL PHASE OF RA WITH ABATACEPT (APIPPRA) TRIAL
Org: King’s College London, Guy’s and St Thomas’ NHS Foundation Trust, University of Birmingham, Sandwell and West Birmingham NHS Trust, Catholic University of the Sacred Heart, Rome, Italy,
Abstract
A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME (PSS)
Org: UCB Pharma, Newcastle University, Strasbourg University Hospital, University of Palermo, Université Paris-Sud,
Abstract
AUTOLOGOUS STEM CELL TRANSPLANTATION INTERNATIONAL SCLERODERMA TRIAL
Org: Newcastle University, Hopital Saint-Louis, University Hospital Basel and University of Basel,